Abstract:The DNA damage response (DDR) encompasses the detection and repair of DNA lesions and is fundamental to the maintenance of genome integrity. Germline DDR alterations underlie hereditary chromosome instability syndromes by promoting the acquisition of pathogenic structural variants in hematopoietic cells, resulting in increased predisposition to hematologic malignancies. Also frequent in hematologic malignancies are somatic mutations of DDR genes, typically arising from replication stress triggered by oncogene activation or deregulated tumor proliferation that provides a selective pressure for DDR loss. These defects impair homology-directed DNA repair or replication stress response, leading to an excessive reliance on error-prone DNA repair mechanisms that results in genomic instability and tumor progression. In hematologic malignancies, loss-of-function DDR alterations confer clonal growth advantage and adverse prognostic impact, but may also provide therapeutic opportunities. Selective targeting of functional dependencies arising from these defects could achieve synthetic lethality, a therapeutic concept exemplified by inhibition of poly(ADP-ribose) polymerase or the ATR-CHK1-WEE1 axis in malignancies harboring the BRCAness phenotype or genetic defects that increase replication stress. Furthermore, the role of DDR defects as a source of tumor immunogenicity, as well as their impact on the crosstalk between DDR, inflammation and tumor immunity are increasingly recognized, thus providing rationale for combining DDR modulation with immune modulation. The nature of the DDR-immune interface and the cellular vulnerabilities conferred by DDR defects may nonetheless be disease-specific and remain incompletely understood in many hematologic malignancies. Their comprehensive elucidation will be critical for optimizing therapeutic strategies to target DDR defects in these diseases.-

Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies

Targeting DNA damage response pathways in cancer

The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy

DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies

DNA Damage Checkpoint Recovery and Cancer Development

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

DNA Damage Response and Immune Defense

Review: Protein O-GlcNAcylation Regulates DNA Damage Response: A Novel Target for Cancer Therapy.

DNA damage repair and cancer immunotherapy

Alterations of DNA damage repair in cancer: from mechanisms to applications

The Roles of DNA Damage Response Machineries in Maintaining Genome Stability&Cellular Homeo-stasis

Regulators in the DNA Damage Response.

Recent Progress in DNA Damage Response-Targeting PROTAC Degraders

Cell Cycle and DNA Repair Regulation in the Damage Response: Protein Phosphatases Take Over the Reins

DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities

DNA damage response in breast cancer and its significant role in guiding novel precise therapies

Advancing cancer therapy: new frontiers in targeting DNA damage response

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

Tissue specificity of DNA damage response and tumorigenesis.

When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity

The DNA damage response relies on the characteristics of ionizing particles in myogenic cells